Health & Fitness
Health and Fitness
Health and Fitness
Sat, September 10, 2011
Fri, September 9, 2011
Thu, September 8, 2011 Diagnocure To Present At Rodman &; Renshaw Annual Global Investment Conference On September 13, 2011
QUEBEC CITY, Sept. 8, 2011 /CNW Telbec/ - DiagnoCure, Inc. (TSX: CUR), a life sciences company that develops and commercializes high‐value cancer diagnostic tests, today announced that the Company will present a review of its business strategy at the Rodman & Renshaw Annual Global Investment Conference on Tuesday, September 13, 2011, at 4:30 PM (ET). The conference is being held in New York City from September 11 through 13, 2011.
The event will be webcast live through DiagnoCure's website at [ www.diagnocure.com ] (select Investors, Presentations).
More information on the Rodman & Renshaw Annual Global Investment Conference can be found at [ www.rodm.com/conferences ].
About DiagnoCure
DiagnoCure (TSX: CUR) is a life sciences company that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Company launched the PrevistageTM GCC Colorectal Cancer Staging Test through its U.S. CLIA laboratory, and granted the worldwide exclusive rights to this test to Signal Genetics in June 2011. The Company also has a strategic alliance with Gen-Probe (NASDAQ: GPRO) for the development and commercialization of a second-generation prostate cancer test using PCA3, DiagnoCure's proprietary molecular biomarker. The PROGENSA® PCA3 test is commercialized in Europe under CE mark and was recently approved in Canada; in the United States, the test is commercialized through clinical laboratories using PCA3 analyte specific reagents from Gen‐Probe; a PMA application was filed with the FDA. For more information, visit [ www.diagnocure.com ].
Forward‐looking statements
This release contains forward‐looking statements that involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expected. By their very nature, forward‐looking statements are based on expectations and hypotheses and also involve risks and uncertainties, known and unknown, many of which are beyond DiagnoCure's control. As a result, investors are cautioned not to place undue reliance on these forward‐looking statements. The forward-looking statements regarding the outcome of research and development projects, clinical studies and future revenues are based on management expectations. In addition, the reader is referred to the applicable general risks and uncertainties described in DiagnoCure's most recent Annual Information Form under the heading "Risk Factors". DiagnoCure undertakes no obligation to publicly update or revise any forward‐looking statements contained herein unless required by the applicable securities laws and regulations.
